It's something doctors and researchers have started noticing, but as yet we don't have much in the way of solid evidence about a connection
At the 12mg maintenance dose, approximately 21% of participants reported constipation
The full effect on insulin secretion, gastric emptying, and appetite regulation becomes apparent
The GIP receptor activation in tirzepatide may contribute to better preservation of muscle mass during weight loss, though the evidence is not yet definitive
Ultimately, whether microdosing becomes mainstream will depend on future clinical evidence
The reduction in LFC was significantly correlated (p0.0006) with baseline LFC (=-0.71), reductions in visceral adipose tissue, and abdominal subcutaneous adipose tissue in the tirzepatide groups [63]